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Abstract
The prognosis of patients with ANCA-associated vasculitis has improved over the past decades, but overall survival
rates are still unsatisfactory. Recent research has focused on complications of immunosuppressive measures and
comorbidities of ANCA-associated vasculitis. This review focuses on thromboembolic and cardiovascular events.
A considerably increased risk of thromboembolic events has been reported, which is associated with active disease
and impaired coagulation factors. There is mounting evidence that a hypercoagulable state is present even in
patients in remission, and studies investigating the impact of tailored anticoagulation are needed to reduce the
burden of thromboembolism. Cardiovascular mortality is one of the leading causes of death and accelerated
atherosclerosis is frequently observed in patients with ANCA-associated vasculitis. A high frequency of patients
develops hypertension, diabetes mellitus and hypercholesterolaemia, either as a consequence of immunosuppres-
sion or associated with the underlying disease. The current control of modifiable cardiovascular risk factors is
insufficient and thorough reviews should be performed periodically. Treatment of these risk factors should be
adopted according to current recommendations related to individual cardiovascular risk prediction.
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Introduction
Despite improved survival rates of patients with ANCA-
associated vasculitis, comprising granulomatosis with
polyangiitis (GPA), microscopic polyangiitis and eosino-
philic granulomatosis with polyangiitis (EGPA), the over-
all mortality rate is still increased 2.7-fold in comparison
with the general population [1]. Within the first year
of diagnosis, infectious complications and active vascu-
litis are the leading causes of mortality, while thereafter
cardiovascular events are the most common complica-
tion leading to death, followed by malignancies and
infections. Severely impaired renal function, advancing
age and high disease activity at baseline are independ-
ent predictors for patient survival [2]. A cohort of cases
diagnosed from 2002 to 2017 confirmed that infections,
malignancies and cardiovascular disease are the most
common causes of death. A standardized mortality
rate of 2.3 fold higher for cardiovascular mortality was
reported, with a significant association of MPO-ANCA
vasculitis with cardiovascular death, while a non-signifi-
cantly increased mortality was reported for proteinase 3
(PR3)-ANCA positive disease. After adjustment for base-
line creatinine, age and sex, cases with MPO-ANCA vas-
culitis retained a significantly higher risk of fatal
cardiovascular events [3].
These findings highlight the importance of cardiovas-
cular disease in the context of ANCA-associated vascu-
litis. In this review we will focus on early comorbidities
associated with active disease, i.e. venous thrombo-
embolic events (VTEs), and discuss the impact of
inflammation on the onset of late comorbidities, strat-
egies to diagnose cardiac involvement and the need to
optimize management of cardiovascular risk factors to
reduce the burden of cardiovascular events.
Rheumatology key messages
. Cardiovascular events are among the leading causes of morbidity and mortality in ANCA-associated vasculitis.
. Active ANCA-associated vasculitis is linked with an increased risk of developing venous thromboembolic
events.
. Cardiovascular risk factors in vasculitis need to be controlled to achieve the respective target values.
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VTEs are frequently observed in patients with ANCA-
associated vasculitis. The Wegenerã s Granulomatosis
Etanercept Trial (WGET) trial enrolled patients with GPA
and found an incidence rate of 8.9%, corresponding to
7.0 events per 100 person-years. The median time
from enrolment during active disease to VTE was
2.1 months and there was a clear association of active
disease and VTE [4]. In an analysis of the Danish
National Hospital Register, Faurschou et al. observed
incidence rate ratios of 25.7 and 20.2 for pulmonary
embolism and deep venous thrombosis, respectively,
within the first two years of diagnosis. Most vascular
events occurred during episodes of treatment for active
disease [5]. Further studies evaluated the association
of VTEs and found an incidence rate of 8–10%.
Several risk factors were identified, including patient’s
age, male sex, a history of VTE and stroke with motor
deficit. A lower risk was described in those with lower
limb motor neuropathy and a diagnosis of PR3-ANCA
vasculitis [6]. A recent analysis of trials by the
European Vasculitis Society (EUVAS) identified that
CRP, higher baseline creatinine, and cutaneous and
gastrointestinal involvement contributed to the risk of
VTE. Among 417 participants with complete datasets,
41 (9.8%) VTEs occurred [7]. Recent studies aimed to
understand the hypercoagulable state of patients with
ANCA-associated vasculitis and identified several
mechanisms. A number of patients with ANCA-
associated vasculitis have presence of
anti-plasminogen and anti-tissue plasminogen activator
antibodies, and exhibit retarded fibrinolysis. Anti-
plasminogen antibody positivity was more frequent in
patients with severely impaired renal function at base-
line [8]. The alternative complement pathway is crucial-
ly involved in disease pathogenesis. Mechanistic
studies revealed that C5a-primed neutrophils produce
tissue factor-expressing microparticles and neutrophil
extracellular traps, both crucially involved in perpetuat-
ing inflammation, after stimulation with ANCA. Tissue
factor-expressing microparticles and neutrophil extra-
cellular traps were capable of inducing thrombin gener-
ation [9]. During active disease, crucial coagulation
parameters are impaired, including increased platelet
counts, fibrinogen, prothrombin fragments and
D-dimer. Higher levels of factor VIII, von Willebrand
factor, and ristocetin cofactor activity and antigen per-
sist during vasculitis remission [10]. Analysis of coagu-
lation factors during stable remission revealed
increased levels of endogenous thrombin potential, fac-
tor VIII and tissue factor pathway inhibitor in patients
with ANCA-associated vasculitis [11]. This not only
underlines the impact of active disease on the coagula-
tion status, but also reveals that patients in stable re-
mission are hypercoagulable and may exhibit a higher
VTE risk.
Myocardial infarction and stroke
Elderly patients with ANCA-associated vasculitis are at
an increased risk of developing cardiovascular disease
[12]. Using health care data from British Columbia,
Avi~na-Zubieta et al. [13] reported an increased incidence
of myocardial infarction in a fully adjusted model (even
for outpatient visits and glucocorticoid use) of patients
with GPA with a relative risk (RR) of 1.86, while the rate
of ischaemic stroke was non-significantly increased
(RR of 1.50). Most events occurred within the first year
of diagnosis, with a steady decrease in the incidence
during the following years. The risk for ischaemic heart
disease in GPA was further studied by using the Danish
National Hospital Register. Overall, a 1.9-fold increased
risk was reported, and this was mainly attributable to
acute myocardial infarction and other diagnoses listed
within International Classification of Diseases 8/10
blocks of ischaemic heart disease. Among risk factors,
elderly patients 50 years at the time of diagnosis, male
sex and patients receiving a high cumulative dose of
CYC (>36 g) were identified as significant predictors
[14]. Again, the incidence of stroke either in the first two
years after diagnosis or thereafter did not differ from a
matched background population, with an incident rate
ratio of 1.4 [5].
In contrast, the calculated comparative morbidity fig-
ure (CMF) in a cohort study from southern France
revealed increased rates of ischaemic stroke incidence
(CMF 4.65) and, in line with reports from other data-
bases, coronary artery disease (CMF 4.22). Smoking at
the time of diagnosis was an independent predictor of
major cardiovascular event and as expected, a history
of coronary artery disease was associated with another
event during follow-up [15]. In a retrospective analysis
with a matched cohort comprising patients with chronic
kidney disease, an excess of cardiovascular events
with a hazard ratio of 2.23 for the cohort with ANCA-
associated vasculitis could be confirmed. A history of
cardiovascular disease, dialysis dependency and smok-
ing were associated with cardiovascular events. Elderly
patients, those with a lower estimated glomerular filtra-
tion rate and higher serum cholesterol levels at baseline
were particularly at an increased risk [16].
A recent meta-analysis of observational studies high-
lighted an increased risk for all cardiovascular events.
The RR of ischaemic heart disease was elevated (RR of
1.60), while there was a trend towards more cerebrovas-
cular accidents (RR of 1.20) [17]. While an increase in
cardiac events was observed in all studies, the impact
of vasculitis on the risk of cerebrovascular disease
needs to be investigated in larger studies with well-
defined populations. Again, several mechanistic studies
have emerged in the past suggesting explanations for
the increased risk of cardiovascular disease in patients
with ANCA-associated vasculitis. Carotid intima-media
thickness measurements in GPA patients during remis-
sion revealed increased intima-media thickness com-
pared with matched controls, and these alterations were
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associated with raised levels of biomarkers indicating in-
flammation [18]. Endothelium-dependent vasodilatation
was impaired in patients with GPA and EGPA as meas-
ured at two different sites, and inversely correlated with
age [19]. In active disease, the augmentation index and
the pulse wave velocity were elevated, while the aortic
timing of the reflected waveform was decreased. These
changes normalized upon remission and did not differ
from analysis of matched controls [20].
Why should we perform cardiac imaging?
Echocardiography is a helpful tool to detect structural
cardiac abnormalities. A cross-sectional study found
lower left-ventricle ejection fraction, higher right ventricle
systolic pressure, higher mean E/E0 ratio as a sign of
higher left ventricle filling pressure, and increased
frequencies of valvular regurgitation in patients with
ANCA-associated vasculitis compared with age- and
gender-matched controls assessed within a period of
3 months from initial diagnosis. Pericardial effusion and
left ventricular hypertrophy were present in one-fifth of
the subjects. Differences among disease phenotypes
were reported [21]. A prospective cohort study including
50 EGPA and 41 GPA patients in remission used a step-
up approach to investigate cardiac involvement. ECG
and echocardiography identified cardiac involvement in
62% EGPA and 46% GPA patients, which was further
increased to 66 and 61% in cases undergoing cardiac
MRI. Upon indication, endomyocardial biopsies and cor-
onary artery assessment were performed and found a
significant proportion of abnormalities. Cardiac involve-
ment assessed by ECG or echocardiography in patients
with ANCA-associated vasculitis was a strong predictor
for all-cause and cardiovascular mortality during follow-
up [22]. Cardiac MRI revealed reduced left-ventricle
ejection fraction values in subjects with late gadolinium
enhancement. While late gadolinium enhancement
was present in 43% of patients in a cross-sectional
study, a large proportion of cases with EGPA and GPA
presented higher native T1 and T2 mapping values,
which are suggestive for both chronic (fibrosis) and
acute (inflammation) changes in the myocardium [23].
Are we adequately controlling
cardiovascular risk factors?
A recent study investigated the change in the lipid
profile of participants from the Rituximab for ANCA-
Associated Vasculitis (RAVE) trial. A significant increase
of total cholesterol, low-density lipoprotein and
apolipoprotein B was observed from baseline to month
6. Further analysis highlighted that these changes in the
above-mentioned parameters are only observed in
patients with a new diagnosis of ANCA-associated vas-
culitis (þ19, þ32 and þ12%, respectively). PR3-ANCA-
positive vasculitis and patients achieving remission off
steroids by month 6 had increases in total cholesterol,
low-density lipoprotein and apolipoprotein B, while this
was not observed in cases with MPO-ANCA vasculitis
or those not achieving remission without steroids [24].
This underlines the importance of regularly controlling
lipid parameters once patients achieve remission.
Factors such as fasting or weight loss during active
disease impair cholesterol synthesis, which may explain
lower levels at baseline. Assessing the cardiovascular
risk of patients with ANCA-associated vasculitis seems
pivotal to reduce the increased risk of cardiovascular
events and mortality. Long-term follow-up of six EUVAS
trials identified 302 patients followed for a mean of
7.1 years. The frequency of hypertension and diabetes
increased by 36.7 and 9.3%, respectively, over time
[25]. A recent multicentre study aimed to investigate the
management of cardiovascular risk factors in patients
with ANCA-associated vasculitis compared with a con-
trol group comprising patients with hypertension. Almost
one-third of participants with ANCA-associated vascu-
litis were at very high 10-year cardiovascular risk and
more patients had hyperlipidaemia compared with the
control group. A majority (75.7%) had a low-density lip-
oprotein-cholesterol target according to their cardiovas-
cular risk level, but only 10% of these patients achieved
their target levels. Lipoprotein(a) levels were elevated in
a quarter of patients with ANCA-associated vasculitis.
A better control of hypertension was recorded in cases
with an albumin excretion rate <30 mg/day. Over 75%
reached the target blood pressure of 140/90 mmHg,
while among those with an albumin excretion rate of
>30 mg/day only 7/20 patients achieved their proposed
target blood pressure of 130/80 mmHg [26]. This
study clearly highlights that systematic assessment of
a patient’s individual cardiovascular risk needs to be
performed periodically, and medication needs to be
adopted accordingly. In order to assess the potential ef-
ficacy of lipid-lowering measures, the French Vasculitis
Study Group is currently conducting a randomized con-
trolled trial (STATVAS, NCT02117453), which is assign-
ing patients in remission to either rosuvastatin 20 mg/
day or placebo. The primary endpoint is defined as
change in mean intima-media thickness for six prede-
fined sites after 24 months. Several secondary outcome
measures will assess potential differences in both
groups.
Conclusion
In recent years, research in ANCA-associated vasculitis
has focused on comorbidities attributable to these dis-
eases. Early and late onset comorbidities have a signifi-
cant impact on quality of life, morbidity and mortality
rates. The latter is still unsatisfactory, and cardiovascular
complications are among the principal complications
leading to death [1, 2]. VTEs generally occur during
disease activity [4] and there is a strong need to identify
potential predictors that would allow for risk stratifica-
tion. Studies focusing on this complication are on the
way and further mechanistic work is necessary to
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potentially provide tailored anticoagulation weighting risk
(i.e. increased bleeding risk) and benefit. Mortality due
to cardiac events is still increased, and accelerated
atherosclerosis and impaired vasodilatation [18, 20] are
proposed mechanisms leading to cardiovascular disease.
The frequency of cardiovascular involvement has been
underestimated and further diagnostic approaches should
be considered in patients at risk [22]. Recent studies
highlighted that patients with ANCA-associated vasculitis
frequently develop cardiovascular risk factors as a conse-
quence of immunosuppressive treatment and that these
risk factors are poorly controlled. We suggest that cardio-
vascular risk factors are determined in detail periodically
(i.e. every 6 months), and that medication to treat hyper-
cholesterolaemia, hypertension and diabetes mellitus is
adjusted to achieve respective target values. Moreover,
the importance of general and lifestyle modifying meas-
ures needs to be accentuated, and patients should be
advised to stop smoking and perform regular exercise.
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